News

Pulmonology Advisor2d
Enflonsia Approved for RSV Disease Prevention in Infants
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...
Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
Fierce Pharma6d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
Scripps News on MSN3d
FDA Approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
BioPharma Dive6d
Merck antibody drug for RSV approved by FDA
Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...
PharmExec5d
FDA Approves Merck’s Enflonsia to Prevent Respiratory Syncytial Virus
Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...
Zacks Investment Research on MSN5d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV ...
Clinical Trials Arena4d
MSD’s Enflonsia receives FDA approval for RSV prophylaxis
Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
STAT6d
Merck’s RSV antibody treatment for infants is approved by FDA
The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.
katc4d
FDA Approves Merck’s Enflonsia to prevent RSV in infants
Merck said Enflonsia is administered as a single 105 mg dose and provides protection for up to five months — the typical length of an RSV season. “Enflonsia combines dosing convenience with ...